

# Dorothy K Hatsukami

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2925761/publications.pdf>

Version: 2024-02-01

316  
papers

14,360  
citations

17429

63  
h-index

30894

102  
g-index

318  
all docs

318  
docs citations

318  
times ranked

9530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. <i>Human Molecular Genetics</i> , 2007, 16, 36-49.	1.4	784
2	Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. <i>Nicotine and Tobacco Research</i> , 2007, 9, 555-570.	1.4	472
3	Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. <i>JAMA Network Open</i> , 2018, 1, e185937.	2.8	361
4	Randomized Trial of Reduced-Nicotine Standards for Cigarettes. <i>New England Journal of Medicine</i> , 2015, 373, 1340-1349.	13.9	312
5	Effect of nicotine on the tobacco withdrawal syndrome. <i>Psychopharmacology</i> , 1984, 83, 82-87.	1.5	280
6	New and traditional smokeless tobacco: Comparison of toxicant and carcinogen levels. <i>Nicotine and Tobacco Research</i> , 2008, 10, 1773-1782.	1.4	222
7	Tobacco withdrawal symptoms: An experimental analysis. <i>Psychopharmacology</i> , 1984, 84, 231-236.	1.5	219
8	Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. <i>Addiction</i> , 2010, 105, 343-355.	1.7	207
9	Tobacco addiction. <i>Lancet, The</i> , 2008, 371, 2027-2038.	6.3	196
10	Evaluation of Toxicant and Carcinogen Metabolites in the Urine of E-Cigarette Users Versus Cigarette Smokers. <i>Nicotine and Tobacco Research</i> , 2015, 17, 704-709.	1.4	196
11	Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit ( <i>CHRN</i> ) genes. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 453-466.	1.1	192
12	The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. <i>Tobacco Control</i> , 2009, 18, 324-332.	1.8	187
13	Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 456-467.	2.3	172
14	Effects of Smoking Cessation on Eight Urinary Tobacco Carcinogen and Toxicant Biomarkers. <i>Chemical Research in Toxicology</i> , 2009, 22, 734-741.	1.7	156
15	Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3241-3262.	1.1	151
16	Balancing Consideration of the Risks and Benefits of E-Cigarettes. <i>American Journal of Public Health</i> , 2021, 111, 1661-1672.	1.5	150
17	Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. <i>Psychopharmacology</i> , 1996, 128, 130-138.	1.5	145
18	Quantitation of Acrolein-Derived (3-Hydroxypropyl)mercapturic Acid in Human Urine by Liquid Chromatography-Atmospheric Pressure Chemical Ionization Tandem Mass Spectrometry: Effects of Cigarette Smoking. <i>Chemical Research in Toxicology</i> , 2007, 20, 986-990.	1.7	141

#	ARTICLE	IF	CITATIONS
19	Smokeless tobacco use: harm reduction or induction approach?. <i>Preventive Medicine</i> , 2004, 38, 309-317.	1.6	137
20	A review of the additive health risk of cannabis and tobacco co-use. <i>Drug and Alcohol Dependence</i> , 2016, 166, 6-12.	1.6	136
21	Menstrual phase effects on smoking relapse. <i>Addiction</i> , 2008, 103, 809-821.	1.7	132
22	Reducing tobacco harm: Research challenges and issues. <i>Nicotine and Tobacco Research</i> , 2002, 4, 89-101.	1.4	123
23	Tobacco-specific nitrosamines in new tobacco products. <i>Nicotine and Tobacco Research</i> , 2006, 8, 309-313.	1.4	122
24	Electrolyte and other physiological abnormalities in patients with bulimia. <i>Psychological Medicine</i> , 1983, 13, 273-278.	2.7	118
25	Relationships between Cigarette Consumption and Biomarkers of Tobacco Toxin Exposure. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2963-2968.	1.1	115
26	Similar Uptake of Lung Carcinogens by Smokers of Regular, Light, and Ultralight Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 693-698.	1.1	114
27	Women and Smoking: The Effect of Gender on the Epidemiology, Health Effects, and Cessation of Smoking. <i>Current Addiction Reports</i> , 2014, 1, 53-60.	1.6	114
28	Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 880.	3.8	113
29	Combination Varenicline and Bupropion SR for Tobacco-Dependence Treatment in Cigarette Smokers. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 155.	3.8	112
30	Affective disorder and substance abuse in women with bulimia. <i>Psychological Medicine</i> , 1984, 14, 701-704.	2.7	109
31	Gender differences in the pharmacology of nicotine addiction. <i>Addiction Biology</i> , 1998, 3, 383-404.	1.4	104
32	Evaluation of Carcinogen Exposure in People Who Used "Reduced Exposure" Tobacco Products. <i>Journal of the National Cancer Institute</i> , 2004, 96, 844-852.	3.0	104
33	Oral spit tobacco: addiction, prevention and treatment. <i>Nicotine and Tobacco Research</i> , 1999, 1, 21-44.	1.4	102
34	Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015, 33, 952-963.	0.8	102
35	The Role of Tobacco Cessation, Antiplatelet and Lipid-Lowering Therapies in the Treatment of Peripheral Arterial Disease. <i>Vascular Medicine</i> , 1997, 2, 243-251.	0.8	101
36	Similar Exposure to a Tobacco-Specific Carcinogen in Smokeless Tobacco Users and Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1567-1572.	1.1	99

#	ARTICLE	IF	CITATIONS
37	Effects of Reduced Cigarette Smoking on the Uptake of a Tobacco-Specific Lung Carcinogen. <i>Journal of the National Cancer Institute</i> , 2004, 96, 107-115.	3.0	97
38	Changing Smokeless Tobacco Products. <i>American Journal of Preventive Medicine</i> , 2007, 33, S368-S378.	1.6	97
39	Nicotine reduction revisited: science and future directions. <i>Tobacco Control</i> , 2010, 19, e1-e1.	1.8	90
40	Applying Tobacco Carcinogen and Toxicant Biomarkers in Product Regulation and Cancer Prevention. <i>Chemical Research in Toxicology</i> , 2010, 23, 1001-1008.	1.7	89
41	NIH Electronic Cigarette Workshop: Developing a Research Agenda. <i>Nicotine and Tobacco Research</i> , 2015, 17, 259-269.	1.4	88
42	Reconciling Human Smoking Behavior and Machine Smoking Patterns: Implications for Understanding Smoking Behavior and the Impact on Laboratory Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3305-3320.	1.1	87
43	Effective Tobacco Dependence Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 1768.	3.8	85
44	Physiologic and subjective changes from smokeless tobacco withdrawal. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 103-107.	2.3	84
45	Attitudes and knowledge about nicotine and nicotine replacement therapy. <i>Nicotine and Tobacco Research</i> , 2006, 8, 435-446.	1.4	83
46	Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	79
47	Analysis of 23 Polycyclic Aromatic Hydrocarbons in Smokeless Tobacco by Gas Chromatography~Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2010, 23, 66-73.	1.7	78
48	Treatment of adolescent smokers with the nicotine patch. <i>Nicotine and Tobacco Research</i> , 2003, 5, 515-526.	1.4	77
49	Biomarkers to assess the utility of potential reduced exposure tobacco products. <i>Nicotine and Tobacco Research</i> , 2006, 8, 169-191.	1.4	77
50	The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 708-718.	1.1	77
51	Harm Reduction Approaches to Reducing Tobacco-Related Mortality. <i>Annual Review of Public Health</i> , 2004, 25, 377-395.	7.6	76
52	Biomarkers to assess the utility of potential reduced exposure tobacco products. <i>Nicotine and Tobacco Research</i> , 2006, 8, 599-622.	1.4	75
53	Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (<i><sc>CYP2A6</sc></i>). <i>Addiction</i> , 2014, 109, 128-137.	1.7	75
54	CHRNA5 Risk Variant Predicts Delayed Smoking Cessation and Earlier Lung Cancer Diagnosis~A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	72

#	ARTICLE	IF	CITATIONS
55	Effects of behavioral and pharmacological treatment on smokeless tobacco users.. Journal of Consulting and Clinical Psychology, 1996, 64, 153-161.	1.6	71
56	Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures. Chest, 2005, 128, 2528-2537.	0.4	70
57	Quantitation of an Acetaldehyde Adduct in Human Leukocyte DNA and the Effect of Smoking Cessation. Chemical Research in Toxicology, 2007, 20, 108-113.	1.7	70
58	Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention. Nature Reviews Cancer, 2022, 22, 143-155.	12.8	70
59	Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms.. Experimental and Clinical Psychopharmacology, 1995, 3, 163-173.	1.3	69
60	Dose-Response Effects of Spectrum Research Cigarettes. Nicotine and Tobacco Research, 2013, 15, 1113-1121.	1.4	69
61	Smokeless tobacco control in 180 countries across the globe: call to action for full implementation of WHO FCTC measures. Lancet Oncology, The, 2019, 20, e208-e217.	5.1	69
62	Tobacco harm reduction: Past history, current controversies and a proposed approach for the future. Preventive Medicine, 2020, 140, 106099.	1.6	68
63	Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers. Cancer Prevention Research, 2016, 9, 396-405.	0.7	67
64	Kinetics of DNA Adduct Formation in the Oral Cavity after Drinking Alcohol. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 601-608.	1.1	66
65	Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clinical Cancer Research, 2015, 21, 514-525.	3.2	66
66	Effects of short-term use of nicotine gum in pregnant smokers*. Clinical Pharmacology and Therapeutics, 1996, 59, 654-661.	2.3	65
67	Safety of Cotinine in Humans: Physiologic, Subjective, and Cognitive Effects. Pharmacology Biochemistry and Behavior, 1997, 57, 643-650.	1.3	65
68	A 2â€”5 year follow-up study of patients treated for bulimia. International Journal of Eating Disorders, 1989, 8, 157-165.	2.1	64
69	Presence of the Carcinogen <i>N</i>-Nitrosornicotine in the Urine of Some Users of Oral Nicotine Replacement Therapy Products. Cancer Research, 2009, 69, 8236-8240.	0.4	63
70	Withdrawal and pre-menstrual symptomatology during the menstrual cycle in short-term smoking abstinence: Effects of menstrual cycle on smoking abstinence. Nicotine and Tobacco Research, 1999, 1, 129-142.	1.4	61
71	Nicotine vaccines for smoking cessation. The Cochrane Library, 2012, , CD007072.	1.5	61
72	Reduced nicotine product standards for combustible tobacco: Building an empirical basis for effective regulation. Preventive Medicine, 2014, 68, 17-22.	1.6	61

#	ARTICLE	IF	CITATIONS
73	Reduced Nicotine Content Cigarettes and Nicotine Patch. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1015-1024.	1.1	60
74	Pharmacodynamic effects of cotinine in abstinent cigarette smokers. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 581-590.	2.3	59
75	Symptoms of tobacco withdrawal from total cigarette cessation versus partial cigarette reduction. <i>Psychopharmacology</i> , 1988, 94, 242-7.	1.5	58
76	Developing the science base for reducing tobacco harm. <i>Nicotine and Tobacco Research</i> , 2007, 9, 537-553.	1.4	58
77	Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 1668-73.	1.1	58
78	Efficacy of Nicotine Patch in Smokers With a History of Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2003, 27, 946-954.	1.4	56
79	Nicotine Reduction: Strategic Research Plan. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1003-1013.	1.4	55
80	Treatment of spit tobacco users with transdermal nicotine system and mint snuff.. <i>Journal of Consulting and Clinical Psychology</i> , 2000, 68, 241-249.	1.6	54
81	Nicotine Metabolism in African Americans and European Americans: Variation in Glucuronidation by Ethnicity and UGT2B10 Haplotype. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 202-209.	1.3	54
82	Compensatory Smoking from Gradual and Immediate Reduction in Cigarette Nicotine Content. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 472-476.	1.1	52
83	Sex Differences in Hormonal Responses to Stress and Smoking Relapse: A Prospective Examination. <i>Nicotine and Tobacco Research</i> , 2015, 17, 382-389.	1.4	52
84	Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. <i>American Journal of Medicine</i> , 2004, 116, 151-157.	0.6	49
85	Effect of Differing Levels of Tobacco-Specific Nitrosamines in Cigarette Smoke on the Levels of Biomarkers in Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1389-1398.	1.1	49
86	Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. <i>Nicotine and Tobacco Research</i> , 2017, 19, 59-67.	1.4	49
87	Methods to assess potential reduced exposure products. <i>Nicotine and Tobacco Research</i> , 2005, 7, 827-844.	1.4	48
88	Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16. <i>PLoS ONE</i> , 2020, 15, e0237938.	1.1	48
89	Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. <i>Cancer Research</i> , 2002, 62, 129-34.	0.4	48
90	The effects of short-term smokeless tobacco deprivation on performance. <i>Psychopharmacology</i> , 1989, 98, 126-130.	1.5	47

#	ARTICLE	IF	CITATIONS
91	Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial. <i>Addiction</i> , 2017, 112, 349-359.	1.7	47
92	Longitudinal Study of Urinary Phenanthrene Metabolite Ratios: Effect of Smoking on the Diol Epoxide Pathway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2969-2974.	1.1	45
93	Comparison of Polymorphisms in Genes Involved in Polycyclic Aromatic Hydrocarbon Metabolism with Urinary Phenanthrene Metabolite Ratios in Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1805-1811.	1.1	45
94	Subjective Responses to Oral Tobacco Products: Scale Validation. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1259-1264.	1.4	45
95	Flavored and Nonflavored Smokeless Tobacco Products: Rate, Pattern of Use, and Effects. <i>Nicotine and Tobacco Research</i> , 2013, 15, 88-92.	1.4	45
96	Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. <i>Carcinogenesis</i> , 2013, 34, 93-101.	1.3	45
97	Assessing Consumer Responses to Potential Reduced-Exposure Tobacco Products: A Review of Tobacco Industry and Independent Research Methods. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3225-3240.	1.1	44
98	Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. <i>Addiction</i> , 2016, 111, 2208-2216.	1.7	44
99	A Randomized Clinical Trial Examining the Effects of Instructions for Electronic Cigarette Use on Smoking-Related Behaviors and Biomarkers of Exposure. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1524-1532.	1.4	44
100	Interventions to increase use of nicotine gum: A randomized, controlled, single-blind trial. <i>Nicotine and Tobacco Research</i> , 2005, 7, 565-579.	1.4	43
101	Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. <i>Tobacco Control</i> , 2007, 16, 138-142.	1.8	43
102	Monitoring Tobacco-Specific N-Nitrosamines and Nicotine in Novel Marlboro and Camel Smokeless Tobacco Products: Findings From Round 1 of the New Product Watch. <i>Nicotine and Tobacco Research</i> , 2012, 14, 274-281.	1.4	43
103	Ethylation and methylation of hemoglobin in smokers and non-smokers. <i>Carcinogenesis</i> , 2002, 23, 1903-1910.	1.3	42
104	Gender Differences in Smoking Behavior and Dependence Motives Among Daily and Nondaily Smokers. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1408-1413.	1.4	42
105	Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. <i>Psychopharmacology</i> , 1991, 104, 120-124.	1.5	41
106	Effects of high dose transdermal nicotine replacement in cigarette smokers. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 86, 132-139.	1.3	41
107	Conference on abuse liability and appeal of tobacco products: Conclusions and recommendations. <i>Drug and Alcohol Dependence</i> , 2011, 116, 1-7.	1.6	41
108	Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. <i>Addiction</i> , 2017, 112, 6-7.	1.7	41

#	ARTICLE	IF	CITATIONS
109	Toxicant Exposure in Cigarette Reducers versus Light Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2355-2358.	1.1	40
110	Smoking reduction fails to improve clinical and biological markers of cardiac disease: A randomized controlled trial. <i>Nicotine and Tobacco Research</i> , 2008, 10, 471-481.	1.4	40
111	Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes – A Meta-Analysis. <i>EBioMedicine</i> , 2016, 11, 219-226.	2.7	40
112	Providing a Science Base for the Evaluation of Tobacco Products. <i>Tobacco Regulatory Science (discontinued)</i> , 2015, 1, 76-93.	0.2	39
113	Persistence and amplitude of cigarette demand in relation to quit intentions and attempts. <i>Psychopharmacology</i> , 2016, 233, 2365-2371.	1.5	39
114	Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial. <i>Addiction</i> , 2017, 112, 156-167.	1.7	39
115	Smokeless tobacco abstinence effects and nicotine gum dose. <i>Psychopharmacology</i> , 1992, 106, 60-66.	1.5	38
116	Nornicotine Nitrosation in Saliva and Its Relation to Endogenous Synthesis of N'-Nitrosornicotine in Humans. <i>Nicotine and Tobacco Research</i> , 2013, 15, 591-595.	1.4	38
117	Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. <i>Drug and Alcohol Dependence</i> , 2015, 154, 278-282.	1.6	38
118	Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers. <i>Npj Precision Oncology</i> , 2018, 2, 17.	2.3	38
119	Perceived risk of harm from cigarettes or smokeless tobacco among U.S. high school seniors. <i>Nicotine and Tobacco Research</i> , 2007, 9, 1191-1196.	1.4	37
120	Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop. <i>Nicotine and Tobacco Research</i> , 2019, 21, 3-13.	1.4	37
121	Analysis of 4-Hydroxy-1-(3-pyridyl)-1-butanone (HPB)-Releasing DNA Adducts in Human Exfoliated Oral Mucosa Cells by Liquid Chromatography–Electrospray Ionization–Tandem Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2013, 26, 37-45.	1.7	36
122	Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers'™ Urine by High Throughput Liquid Chromatography–Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2016, 29, 390-397.	1.7	35
123	Effects of dynorphin A(1-13) on opiate withdrawal in humans. <i>Psychopharmacology</i> , 1998, 137, 326-332.	1.5	34
124	Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. <i>Nicotine and Tobacco Research</i> , 2007, 9, 1309-1323.	1.4	34
125	Detecting longitudinal patterns of daily smoking following drastic cigarette reduction. <i>Addictive Behaviors</i> , 2008, 33, 623-639.	1.7	34
126	Nicotine withdrawal and craving in adolescents: Effects of sex and hormonal contraceptive use. <i>Addictive Behaviors</i> , 2009, 34, 620-623.	1.7	34



#	ARTICLE	IF	CITATIONS
127	Clinical Trials Methods for Evaluation of Potential Reduced Exposure Products. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3143-3195.	1.1	34
128	Evidence Supporting Product Standards for Carcinogens in Smokeless Tobacco Products. <i>Cancer Prevention Research</i> , 2015, 8, 20-26.	0.7	34
129	Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching. <i>Tobacco Control</i> , 2016, 25, 267-274.	1.8	33
130	Effects of 6-Week Use of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness. <i>Nicotine and Tobacco Research</i> , 2019, 21, S38-S45.	1.4	33
131	Exposure to Nicotine and Carcinogens among Southwestern Alaskan Native Cigarette Smokers and Smokeless Tobacco Users. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 934-942.	1.1	32
132	Monitoring Tobacco-Specific N-Nitrosamines and Nicotine in Novel Smokeless Tobacco Products: Findings From Round II of the New Product Watch. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1070-1078.	1.4	32
133	Effect of Oral Snus and Medicinal Nicotine in Smokers on Toxicant Exposure and Withdrawal Symptoms: A Feasibility Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 91-100.	1.1	31
134	Public education about the relative harm of tobacco products: an intervention for tobacco control professionals: Table A1. <i>Tobacco Control</i> , 2014, 23, 385-388.	1.8	31
135	Physical dependence on nicotine gum: effect of duration of use. <i>Psychopharmacology</i> , 1993, 111, 449-456.	1.5	30
136	High Level of Tobacco Carcinogen-Derived DNA Damage in Oral Cells Is an Independent Predictor of Oral/Head and Neck Cancer Risk in Smokers. <i>Cancer Prevention Research</i> , 2017, 10, 507-513.	0.7	30
137	Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. <i>Preventive Medicine</i> , 2018, 117, 8-14.	1.6	30
138	Biomarkers of Exposure Among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, cebp.0539.2018.	1.1	30
139	Tobacco-Specific Nitrosamines (NNAL, NNN, NAT, and NAB) Exposures in the US Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014). <i>Nicotine and Tobacco Research</i> , 2021, 23, 573-583.	1.4	30
140	The Role of Nicotine and Flavor in the Abuse Potential and Appeal of Electronic Cigarettes for Adult Current and Former Cigarette and Electronic Cigarette Users: A Systematic Review. <i>Nicotine and Tobacco Research</i> , 2022, 24, 1332-1343.	1.4	30
141	Oral tobacco products: Preference and effects among smokers. <i>Drug and Alcohol Dependence</i> , 2011, 118, 230-236.	1.6	29
142	Sex differences in response to reduced nicotine content cigarettes. <i>Addictive Behaviors</i> , 2014, 39, 1197-1204.	1.7	29
143	High levels of tobacco-specific N-nitrosamines and nicotine in Chaini Khaini, a product marketed as snus. <i>Tobacco Control</i> , 2015, 24, e271-e274.	1.8	29
144	Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 186-203.	0.2	29

#	ARTICLE	IF	CITATIONS
145	Association of e-Cigarette Use With Discontinuation of Cigarette Smoking Among Adult Smokers Who Were Initially Never Planning to Quit. <i>JAMA Network Open</i> , 2021, 4, e2140880.	2.8	29
146	Effect of Nonnicotine Pharmacotherapy on Smoking Behavior. <i>Pharmacotherapy</i> , 2001, 21, 1530-1548.	1.2	28
147	UGT2B10 Genotype Influences Nicotine Glucuronidation, Oxidation, and Consumption. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1423-1431.	1.1	28
148	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers. <i>Biomarkers</i> , 2011, 16, 491-497.	0.9	27
149	Tobacco and Nicotine Product Testing. <i>Nicotine and Tobacco Research</i> , 2012, 14, 7-17.	1.4	27
150	Randomized Trial of Low-Nicotine Cigarettes and Transdermal Nicotine. <i>American Journal of Preventive Medicine</i> , 2019, 57, 515-524.	1.6	27
151	Age Moderates Smokers' Subjective Response to Very-Low Nicotine Content Cigarettes: Evidence from a Randomized Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2019, 21, 962-969.	1.4	26
152	Cigarette and e-liquid demand and substitution in e-cigarette-naïve smokers. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 233-243.	1.3	26
153	Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks. <i>Tobacco Control</i> , 2018, 27, 420-426.	1.8	25
154	Adolescent smokers' response to reducing the nicotine content of cigarettes: Acute effects on withdrawal symptoms and subjective evaluations. <i>Drug and Alcohol Dependence</i> , 2018, 188, 153-160.	1.6	25
155	E-cigarettes Warning Labels and Modified Risk Statements: Tests of Messages to Reduce Recreational Use. <i>Tobacco Regulatory Science (discontinued)</i> , 2017, 3, 445-458.	0.2	25
156	A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1617-23.	1.1	25
157	2-Phenethyl Isothiocyanate, <i>Glutathione S-transferase M1</i> and <i>T1</i> Polymorphisms, and Detoxification of Volatile Organic Carcinogens and Toxicants in Tobacco Smoke. <i>Cancer Prevention Research</i> , 2016, 9, 598-606.	0.7	24
158	Menthol and Mint Cigarettes and Cigars: Initiation and Progression in Youth, Young Adults and Adults in Waves 1-4 of the PATH Study, 2013-2017. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1318-1326.	1.4	24
159	Effects of nicotine gum on prevalence and severity of withdrawal in female cigarette smokers. <i>Journal of Substance Abuse</i> , 1991, 3, 427-440.	1.1	23
160	Greater reductions in nicotine exposure while smoking very low nicotine content cigarettes predict smoking cessation: Table A1. <i>Tobacco Control</i> , 2015, 24, 536-539.	1.8	23
161	Biochemical Estimation of Noncompliance with Smoking of Very Low Nicotine Content Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 331-335.	1.1	23
162	Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. <i>Drug and Alcohol Dependence</i> , 2016, 167, 228-232.	1.6	23

#	ARTICLE	IF	CITATIONS
163	Tobacco Product Use Patterns, and Nicotine and Tobacco-Specific Nitrosamine Exposure: NHANES 1999-2012. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1525-1530.	1.1	23
164	Surveillance Methods for Identifying, Characterizing, and Monitoring Tobacco Products: Potential Reduced Exposure Products as an Example. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3334-3348.	1.1	22
165	The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 606-615.	1.4	22
166	Assessing the Impact of Conflicting Health Warning Information on Intentions to Use E-Cigarettes -An Application of the Heuristic-Systematic Model. <i>Journal of Health Communication</i> , 2018, 23, 874-885.	1.2	22
167	Smoking- and menstrual-related symptomatology during short-term smoking abstinence by menstrual phase and depressive symptoms. <i>Addictive Behaviors</i> , 2014, 39, 901-906.	1.7	21
168	Isotope Dilution nanoLC/ESI-HRMS Quantitation of Urinary N7-(1-Hydroxy-3-buten-2-yl) Guanine Adducts in Humans and Their Use as Biomarkers of Exposure to 1,3-Butadiene. <i>Chemical Research in Toxicology</i> , 2017, 30, 678-688.	1.7	21
169	Smokeless tobacco topography and toxin exposure. <i>Nicotine and Tobacco Research</i> , 2005, 7, 469-474.	1.4	20
170	Measures for Assessing Subjective Effects of Potential Reduced-Exposure Products. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3209-3224.	1.1	20
171	Increased Pouch Sizes and Resulting Changes in the Amounts of Nicotine and Tobacco-Specific N-Nitrosamines in Single Pouches of Camel Snus and Marlboro Snus. <i>Nicotine and Tobacco Research</i> , 2012, 14, 1241-1245.	1.4	20
172	Nicotine reduction as an increase in the unit price of cigarettes: A behavioral economics approach. <i>Preventive Medicine</i> , 2014, 68, 23-28.	1.6	20
173	Optimized Liquid Chromatography Nanoelectrospray-High-Resolution Tandem Mass Spectrometry Method for the Analysis of 4-Hydroxy-1-(3-pyridyl)-1-butanone-Releasing DNA Adducts in Human Oral Cells. <i>Chemical Research in Toxicology</i> , 2016, 29, 1849-1856.	1.7	20
174	Perceived Health Risks of Snus and Medicinal Nicotine Products. <i>Nicotine and Tobacco Research</i> , 2016, 18, 794-800.	1.4	20
175	Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1093-1099.	1.1	20
176	Reducing the nicotine content of combusted tobacco products sold in New Zealand. <i>Tobacco Control</i> , 2017, 26, e37-e42.	1.8	20
177	Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. <i>PLoS ONE</i> , 2019, 14, e0210104.	1.1	20
178	The Impact of Exclusive Use of Very Low Nicotine Cigarettes on Compensatory Smoking: An Inpatient Crossover Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 880-886.	1.1	20
179	Introduction: Tobacco treatment outcome methodology papers - a series. <i>Nicotine and Tobacco Research</i> , 2002, 4, 147-147.	1.4	19
180	Evaluation of modified risk claim advertising formats for Camel Snus. <i>Health Education Journal</i> , 2017, 76, 971-985.	0.6	19

#	ARTICLE	IF	CITATIONS
181	Cigarette Smokers Versus Cousers of Cannabis and Cigarettes: Exposure to Toxicants. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1383-1389.	1.4	19
182	Individual Differences in the Subjective Response to Smoked Cocaine in Humans. <i>American Journal of Drug and Alcohol Abuse</i> , 2000, 26, 591-602.	1.1	18
183	Characteristics of cigarette smokers seeking treatment for cessation versus reduction. <i>Addictive Behaviors</i> , 2004, 29, 357-364.	1.7	18
184	Measurement of the Heterocyclic Amines 2-Amino-9 <i>H</i> -pyrido[2,3- <i>b</i> ]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5- <i>b</i> ]pyridine in Urine: Effects of Cigarette Smoking. <i>Chemical Research in Toxicology</i> , 2015, 28, 2390-2399.	1.7	18
185	Call to Establish Constituent Standards for Smokeless Tobacco Products. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 9-30.	0.2	18
186	Strategies to Reduce Illicit Trade of Regular Nicotine Tobacco Products After Introduction of a Low-Nicotine Tobacco Product Standard. <i>American Journal of Public Health</i> , 2019, 109, 1007-1014.	1.5	18
187	Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013â€“2014). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 659-667.	1.1	18
188	Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 834-42.	1.1	18
189	The effect of combination oral contraceptives on smoking-related symptomatology during short-term smoking abstinence. <i>Addictive Behaviors</i> , 2015, 41, 148-151.	1.7	17
190	Internalized Smoking Stigma in Relation to Quit Intentions, Quit Attempts, and Current E-Cigarette Use. <i>Substance Abuse</i> , 2017, 38, 330-336.	1.1	17
191	Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. <i>Tobacco Control</i> , 2017, 26, e43-e48.	1.8	17
192	Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage. <i>PLoS ONE</i> , 2019, 14, e0218386.	1.1	17
193	Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers. <i>Nicotine and Tobacco Research</i> , 2019, 21, S63-S72.	1.4	17
194	The Impact of Gradual and Immediate Nicotine Reduction on Subjective Cigarette Ratings. <i>Nicotine and Tobacco Research</i> , 2019, 21, S73-S80.	1.4	17
195	The Role of Compensation in Nicotine Reduction. <i>Nicotine and Tobacco Research</i> , 2019, 21, S16-S18.	1.4	17
196	Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 871-879.	1.1	17
197	Metabolic acidosis as a marker for laxative abuse in patients with bulimia. <i>International Journal of Eating Disorders</i> , 1987, 6, 557-560.	2.1	16
198	Signs and symptoms from nicotine gum abstinence. <i>Psychopharmacology</i> , 1991, 104, 496-504.	1.5	16

#	ARTICLE	IF	CITATIONS
199	Menstrual Phase and Depressive Symptoms Differences in Physiological Response to Nicotine Following Acute Smoking Abstinence. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1091-1098.	1.4	16
200	Subjective response to nicotine by menstrual phase. <i>Addictive Behaviors</i> , 2015, 43, 50-53.	1.7	16
201	Increased acroleinâ€“DNA adducts in buccal brushings of e-cigarette users. <i>Carcinogenesis</i> , 2022, 43, 437-444.	1.3	16
202	Situational factors and patterns associated with smokeless tobacco use. <i>Journal of Behavioral Medicine</i> , 1991, 14, 383-396.	1.1	15
203	Transdisciplinary science applied to the evaluation of treatments for tobacco use. <i>Nicotine and Tobacco Research</i> , 2003, 5, 89-99.	1.4	15
204	Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention. <i>Nicotine and Tobacco Research</i> , 2010, 12, 823-827.	1.4	15
205	Betel Nut (areca) and Smokeless Tobacco Use in Myanmar. <i>Substance Use and Misuse</i> , 2020, 55, 1385-1394.	0.7	15
206	Smokeless tobacco reduction: Preliminary study of tobacco-free snuff versus no snuff. <i>Nicotine and Tobacco Research</i> , 2008, 10, 77-85.	1.4	14
207	Assessing Constituent Levels in Smokeless Tobacco Products: A New Approach to Engaging and Educating the Public. <i>Nicotine and Tobacco Research</i> , 2015, 17, 1354-1361.	1.4	14
208	Differences in exposure to toxic and/or carcinogenic volatile organic compounds between Black and White cigarette smokers. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2021, 31, 211-223.	1.8	14
209	Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Usersâ€“Results from Wave 1 PATH Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1947-1955.	1.1	14
210	Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. <i>Nicotine and Tobacco Research</i> , 2022, 24, 3-9.	1.4	14
211	Patients versus symptomatic volunteers in bulimia nervosa research. <i>International Journal of Eating Disorders</i> , 1988, 7, 837-843.	2.1	13
212	Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms. <i>Addictive Behaviors</i> , 2017, 71, 18-24.	1.7	13
213	Hormonal contraceptive use in smokers: Prevalence of use and associations with smoking motives. <i>Addictive Behaviors</i> , 2018, 77, 187-192.	1.7	13
214	Urinary Cotinine and Cotinine + Trans-3â€“Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013â€“2014). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1175-1184.	1.1	13
215	Lack of effect of 5HT3 antagonist in mediating subjective and behavioral responses to cotinine. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 75, 1-7.	1.3	12
216	Methods Used in Internal Industry Clinical Trials to Assess Tobacco Risk Reduction. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3196-3208.	1.1	12

#	ARTICLE	IF	CITATIONS
217	A Testable Prognostic Model of Nicotine Dependence. <i>Journal of Neurogenetics</i> , 2009, 23, 283-292.	0.6	12
218	Psychometric Characteristics of the Brief Wisconsin Inventory of Smoking Dependence Motives Among a Nonclinical Sample of Smokers. <i>Nicotine and Tobacco Research</i> , 2016, 18, 470-476.	1.4	12
219	Urinary Cyanoethyl Mercapturic Acid, a Biomarker of the Smoke Toxicant Acrylonitrile, Clearly Distinguishes Smokers From Nonsmokers. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1744-1747.	1.4	12
220	Liquid Chromatography-Nanoelectrospray Ionization-High-Resolution Tandem Mass Spectrometry Analysis of Apurinic/Apyrimidinic Sites in Oral Cell DNA of Cigarette Smokers, e-Cigarette Users, and Nonsmokers. <i>Chemical Research in Toxicology</i> , 2021, 34, 2540-2548.	1.7	12
221	Smokeless tobacco: current status and future directions. <i>Addiction</i> , 1991, 86, 559-563.	1.7	11
222	Preliminary study on reducing oral moist snuff use. <i>Drug and Alcohol Dependence</i> , 2003, 70, 215-220.	1.6	11
223	Menstrual phase, depressive symptoms, and allopregnanolone during short-term smoking cessation.. <i>Experimental and Clinical Psychopharmacology</i> , 2013, 21, 427-433.	1.3	11
224	Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco. <i>Tobacco Control</i> , 2018, 27, 352-354.	1.8	11
225	Smoking Topography Characteristics During a 6-Week Trial of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1414-1418.	1.4	11
226	High School Youth and E-cigarettes: The Influence of Modified Risk Statements and Flavors on E-cigarette Packaging. <i>American Journal of Health Behavior</i> , 2020, 44, 130-145.	0.6	11
227	Mouth-Level Nicotine Intake Estimates from Discarded Filter Butts to Examine Compensatory Smoking in Low Nicotine Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 643-649.	1.1	11
228	Risk Perceptions of Low Nicotine Cigarettes and Alternative Nicotine Products across Priority Smoking Populations. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5311.	1.2	11
229	"I actually finally feel like the cigarettes aren't controlling me." Interviews with participants smoking very low nicotine content cigarettes during a residential study. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108465.	1.6	11
230	Pharmacological and Behavioral Strategies for Smoking Cessation. <i>Journal of Clinical Psychology in Medical Settings</i> , 1999, 6, 11-38.	0.8	10
231	Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings. <i>Nicotine and Tobacco Research</i> , 2016, 18, 2162-2168.	1.4	10
232	Cigarette Nicotine Content as a Moderator of the Relationship Between Negative Affect and Smoking. <i>Nicotine and Tobacco Research</i> , 2017, 19, 1080-1086.	1.4	10
233	CYP2A6 metabolism in the development of smoking behaviors in young adults. <i>Addiction Biology</i> , 2018, 23, 437-447.	1.4	10
234	Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. <i>PLoS ONE</i> , 2019, 14, e0215853.	1.1	10

#	ARTICLE	IF	CITATIONS
235	Effects of 2-Phenethyl Isothiocyanate on Metabolism of 1,3-Butadiene in Smokers. <i>Cancer Prevention Research</i> , 2020, 13, 91-100.	0.7	10
236	Impact of Cigarette Filter Ventilation on U.S. Smokers' Perceptions and Biomarkers of Exposure and Potential Harm. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 38-44.	1.1	10
237	E-cigarette use and change in plans to quit cigarette smoking among adult smokers in the United States: Longitudinal findings from the PATH Study 2014â€“2019. <i>Addictive Behaviors</i> , 2022, 124, 107124.	1.7	10
238	Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence.. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 223-232.	1.3	10
239	Urinary Nicotine Metabolites and Self-Reported Tobacco Use Among Adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013â€“2014. <i>Nicotine and Tobacco Research</i> , 2022, 24, 768-777.	1.4	10
240	Effectiveness of Over-the-Counter Nicotine Replacement Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 3109.	3.8	9
241	Comparing an Immediate Cessation Versus Reduction Approach to Smokeless Tobacco Cessation. <i>Nicotine and Tobacco Research</i> , 2012, 14, 902-909.	1.4	9
242	Ending tobacco-caused mortality and morbidity: the case for performance standards for tobacco products. <i>Tobacco Control</i> , 2013, 22, i36-i37.	1.8	9
243	Preference for Flavored Noncombustible Nicotine Products Among Smokers Motivated to Switch From Cigarettes. <i>Nicotine and Tobacco Research</i> , 2016, 18, 892-893.	1.4	9
244	Sex differences in physiological response to the combination of stress and smoking. <i>International Journal of Psychophysiology</i> , 2017, 118, 27-31.	0.5	9
245	Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus. <i>Nicotine and Tobacco Research</i> , 2018, 20, 1292-1300.	1.4	9
246	Reducing the relative value of cigarettes: Considerations for nicotine and non-nicotine factors. <i>Neuropharmacology</i> , 2020, 175, 108200.	2.0	9
247	The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers. <i>Cancer Prevention Research</i> , 2020, 13, 483-492.	0.7	9
248	Cardiovascular Risk Factor and Disease Measures from the Population Assessment of Tobacco and Health (PATH) Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7692.	1.2	9
249	Cigarette smoking enhances the metabolic activation of the polycyclic aromatic hydrocarbon phenanthrene in humans. <i>Carcinogenesis</i> , 2021, 42, 570-577.	1.3	9
250	Constituent Variations in Smokeless Tobacco Purchased in Mumbai, India. <i>Tobacco Regulatory Science (discontinued)</i> , 2017, 3, 305-314.	0.2	9
251	Variation in Human Plasma Cholinesterase Activity During Low-Dose Cocaine Administration. <i>Journal of Toxicology: Clinical Toxicology</i> , 1998, 36, 3-9.	1.5	8
252	Use of hormonal contraceptives and smoking cessation: A preliminary report. <i>Addictive Behaviors</i> , 2018, 76, 236-242.	1.7	8

#	ARTICLE	IF	CITATIONS
253	Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes. <i>Tobacco Control</i> , 2019, 28, 352-355.	1.8	8
254	Betel Quid, Health, and Addiction. <i>Substance Use and Misuse</i> , 2020, 55, 1528-1532.	0.7	8
255	Smoker Response to a Simulated Ban of Menthol Cigarettes: A Pilot Study. <i>Tobacco Regulatory Science (discontinued)</i> , 2015, 1, 236-242.	0.2	8
256	The impact of treatment on meal patterns in patients with bulimia nervosa. <i>International Journal of Eating Disorders</i> , 1989, 8, 167-172.	2.1	7
257	Validation of a Measure of Normative Beliefs About Smokeless Tobacco Use. <i>Nicotine and Tobacco Research</i> , 2016, 18, 801-808.	1.4	7
258	The case for the WHO Advisory Note, Global Nicotine Reduction Strategy. <i>Tobacco Control</i> , 2017, 26, e29-e30.	1.8	7
259	Effects of Filter Ventilation on Behavioral Economic Demand for Cigarettes: A Preliminary Investigation. <i>Nicotine and Tobacco Research</i> , 2018, 20, 1278-1282.	1.4	7
260	A Randomized Clinical Trial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure. <i>Nicotine and Tobacco Research</i> , 2020, 22, 473-481.	1.4	7
261	<i>UGT2B10</i> Genotype Influences Serum Cotinine Levels and Is a Primary Determinant of Higher Cotinine in African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1673-1678.	1.1	7
262	An Evaluation of Potential Unintended Consequences of a Nicotine Product Standard: A Focus on Drinking History and Outcomes. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1168-1175.	1.4	7
263	Effects on Smoking Behavior of Switching Menthol Smokers to Non-menthol Cigarettes. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1921-1927.	1.4	7
264	Regulatory Approaches and Implementation of Minimally Addictive Combusted Products. <i>Nicotine and Tobacco Research</i> , 2022, 24, 453-462.	1.4	7
265	Recommendations to researchers for aiding in increasing American Indian representation in genetic research and personalized medicine. <i>Personalized Medicine</i> , 2021, 18, 67-74.	0.8	7
266	Comparing IV and Non-IV Cocaine Users: Characteristics of a Sample of Cocaine Users Seeking to Participate in Research. <i>American Journal on Addictions</i> , 1998, 7, 262-271.	1.3	6
267	Perceived risks and reasons to smoke cigarettes during pregnancy among Alaska native women. <i>Ethnicity and Health</i> , 2018, 23, 33-42.	1.5	6
268	Evaluating the utility of subjective effects measures for predicting product sampling, enrollment, and retention in a clinical trial of a smokeless tobacco product. <i>Addictive Behaviors</i> , 2018, 76, 95-99.	1.7	6
269	Blunted opioid regulation of the HPA stress response during nicotine withdrawal: therapeutic implications. <i>Stress</i> , 2021, 24, 529-540.	0.8	6
270	The role of subjective responses in electronic cigarette uptake and substitution in adult smokers. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107999.	1.6	6



#	ARTICLE	IF	CITATIONS
271	Impact of nicotine reduction in cigarettes on smoking behavior and exposure: Are there differences by race/ethnicity, educational attainment, or gender?. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108756.	1.6	6
272	Serum Concentrations of Cotinine and <i>trans</i> -3-Hydroxycotinine in US Adults: Results From Wave 1 (2013–2014) of the Population Assessment of Tobacco and Health Study. <i>Nicotine and Tobacco Research</i> , 2022, 24, 736-744.	1.4	6
273	Circulating leptin and pain perception among tobacco-dependent individuals. <i>Biological Psychology</i> , 2015, 107, 10-15.	1.1	5
274	Application of the Smokeless Tobacco Expectancies Questionnaire to Snus. <i>American Journal of Health Behavior</i> , 2016, 40, 652-658.	0.6	5
275	Effects on time to lapse of switching menthol smokers to non-menthol cigarettes prior to a cessation attempt: a pilot study. <i>Tobacco Control</i> , 2021, 30, 574-577.	1.8	5
276	Chemical characterization of smokeless tobacco products and relevant exposures in users. , 2020, , 121-150.		5
277	Cigarette Smokers Versus Cannabis Smokers Versus Co-users of Cigarettes and Cannabis: A Pilot Study Examining Exposure to Toxicants. <i>Nicotine and Tobacco Research</i> , 2022, 24, 125-129.	1.4	5
278	Early life adversity and appetite hormones: The effects of smoking status, nicotine withdrawal, and relapse on ghrelin and peptide YY during smoking cessation. <i>Addictive Behaviors</i> , 2021, 118, 106866.	1.7	5
279	A Randomized Trial of Nicotine versus No-nicotine E-cigarettes Among African American Smokers: Changes in Smoking and Tobacco Biomarkers. <i>Nicotine and Tobacco Research</i> , 2022, 24, 555-563.	1.4	5
280	The experimental tobacco marketplace: Effects of low-ventilated cigarette exposure. <i>Addictive Behaviors</i> , 2022, 125, 107160.	1.7	5
281	Predictors of E-cigarette and Cigarette Use Trajectory Classes from Early Adolescence to Emerging Adulthood Across Four Years (2013–2017) of the PATH Study. <i>Nicotine and Tobacco Research</i> , 2023, 25, 421-429.	1.4	5
282	Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. <i>Addiction</i> , 2019, 114, 1824-1833.	1.7	4
283	The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller. <i>Nicotine and Tobacco Research</i> , 2019, 21, 338-339.	1.4	4
284	Development and Piloting Testing of an Experimental Tobacco and Nicotine Product Marketplace. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1230-1234.	1.4	4
285	Australian smokers' experiences and perceptions of recessed and firm filter cigarettes. <i>Tobacco Control</i> , 2021, 30, 660-667.	1.8	4
286	Applying Tobacco, Environmental, and Dietary-Related Biomarkers to Understand Cancer Etiology and Evaluate Prevention Strategies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1904-1919.	1.1	4
287	Support for a nicotine reduction policy among participants enrolled in a 20-week trial of very low nicotine content cigarettes. <i>Addictive Behaviors</i> , 2021, 114, 106727.	1.7	4
288	3-Ethenylpyridine Measured in Urine of Active and Passive Smokers: A Promising Biomarker and Toxicological Implications. <i>Chemical Research in Toxicology</i> , 2021, 34, 1630-1639.	1.7	4

#	ARTICLE	IF	CITATIONS
289	A Pilot Product Preference Study of Electronic Cigarettes and Nicotine Gum as Potential Smoking Cessation Aids for African-American Menthol Smokers. <i>Tobacco Regulatory Science</i> (discontinued), 2015, 1, 243-253.	0.2	4
290	Educating the Public on the Health Risks of Very Low Nicotine Content Cigarettes: Results From a US-Based Convenience Sample. <i>Nicotine and Tobacco Research</i> , 2022, 24, 871-880.	1.4	4
291	Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013-2019. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4137.	1.2	4
292	Effect on Tobacco Use and Subjective Measures of Including E-cigarettes in a Simulated Ban of Menthol in Combustible Cigarettes. <i>Nicotine and Tobacco Research</i> , 2022, 24, 1448-1457.	1.4	4
293	Gender differences in snus versus nicotine gum for cigarette avoidance among a sample of US smokers. <i>Drug and Alcohol Dependence</i> , 2016, 168, 8-12.	1.6	3
294	Strong preference for mint snus flavor among research participants. <i>Addictive Behaviors Reports</i> , 2017, 6, 51-55.	1.0	3
295	Reducing Nicotine in Cigarettes to Minimally Addictive Levels. <i>JAMA Psychiatry</i> , 2018, 75, 987.	6.0	3
296	Can the Public Be Educated About Constituents in Smokeless Tobacco? A Three-Wave Randomized Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2021, 23, 161-170.	1.4	3
297	Cigarette Relighting: A Series of Pilot Studies Investigating a Common Yet Understudied Smoking Behavior. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6494.	1.2	3
298	Risk perceptions and continued smoking as a function of cigarette filter ventilation level among US youth and young adults who smoke. <i>Tobacco Control</i> , 2023, 32, 473-479.	1.8	3
299	Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe. <i>Nicotine and Tobacco Research</i> , 2023, 25, 120-126.	1.4	3
300	Nicotine Addiction: Past, Present and Future. Marian W. Fischman Lecture given at the 2007 meeting of CPDD. <i>Drug and Alcohol Dependence</i> , 2008, 92, 312-316.	1.6	2
301	Transdisciplinary Tobacco Use Research Centers: Research achievements and future implications. <i>Nicotine and Tobacco Research</i> , 2009, 11, 1231-1244.	1.4	2
302	Very Low Nicotine Content Cigarettes and Potential Consequences on Cardiovascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 534-541.	0.8	2
303	Commentary on Post <i>et al.</i> (2010): Snus, a cautionary reminder. <i>Addiction</i> , 2010, 105, 747-748.	1.7	1
304	Smokeless tobacco, snus, at admission for percutaneous coronary intervention and future risk for cardiac events. <i>Open Heart</i> , 2019, 6, e001109.	0.9	1
305	Analysis of Multiple Biomarkers Using Structural Equation Modeling. <i>Tobacco Regulatory Science</i> (discontinued), 2020, 6, 266-278.	0.2	1
306	Balfour et al. Respond. <i>American Journal of Public Health</i> , 2022, 112, e2-e3.	1.5	1

#	ARTICLE	IF	CITATIONS
307	A Bayesian hierarchical model for individual participant data meta-analysis of demand curves. <i>Statistics in Medicine</i> , 2022, , .	0.8	1
308	Preparation of a Beverage Containing Freeze-Dried Watercress for a Clinical Trial of Carcinogen and Toxicant Detoxification. <i>Cancer Prevention Research</i> , 2021, , .	0.7	1
309	Early Changes in Puffing Intensity When Exclusively Using Open-Label Very Low Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2022, , .	1.4	1
310	Smokeless tobacco for cigarette cessation? "Authors' reply. <i>Lancet, The</i> , 2008, 372, 1217.	6.3	0
311	Facilitating smoking cessation using reduced nicotine cigarettes: Intervention development and RCT study design. <i>Contemporary Clinical Trials</i> , 2020, 98, 106172.	0.8	0
312	A mixed effects model for analyzing area under the curve of longitudinally measured biomarkers with missing data. <i>Pharmaceutical Statistics</i> , 2021, 20, 1249-1264.	0.7	0
313	Cigarette Filter Ventilation and Biomarkers"Reply. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1450-1450.	1.1	0
314	Immunological Approaches to Nicotine Addiction. , 2006, , 151-166.		0
315	Balfour et al. Respond. <i>American Journal of Public Health</i> , 2022, 112, e5-e6.	1.5	0
316	Response to: Appropriate policy implications of the fact that high content and flavored e-cigarettes have higher abuse liability. <i>Nicotine and Tobacco Research</i> , 2022, , .	1.4	0